{
  "id": 5245602,
  "title": "GC Wellbeing Partner Reports Successful Phase 3 Trial in China",
  "url": "https://urgent.news/2026/09/03/gc-wellbeing-partner-reports-successful-phase-3-trial-in-china",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-03T04:42:29.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=276123"
  },
  "original_language": "en",
  "account": "GC Wellbeing's partner, biotech firm Raziel Therapeutics, has announced the successful completion of a Phase 3 clinical trial in China for their localized fat-dissolving injectable, RZL-012. The drug candidate demonstrated a significant reduction in submental fat after a single treatment cycle, with the response rate more than 30 percentage points higher than the placebo group. The treatment, which aims to irreversibly destroy targeted fat cells, showed favorable safety results, supporting its potential for commercialization. Fosun Pharma and Raziel plan to file a New Drug Application with China's National Medical Products Administration, and are also considering expanding the treatment's use to other body-contouring areas such as the abdomen and thighs. GC Wellbeing, which holds exclusive domestic licensing rights to RZL-012, expects growing demand for GLP-1 obesity treatments to be accompanied by increased demand for body-contouring treatments after weight loss. The company sees China as a key region in the global medical aesthetics market and believes the positive trial results will signal future commercialization in Korea and the expansion of their obesity business.",
  "summary": "A next-generation fat-dissolving drug candidate has reported positive results in a Phase 3 clinical trial in China, showing a significant reduction in submental fat after a single treatment cycle.GC Wellbeing said on Sept. 3 that its partner, biotech company Raziel Therapeutics, had secured topline",
  "key_points": [
    "Raziel Therapeutics' RZL-012 showed 30%+ higher response rate than placebo in China trial",
    "Fosun Pharma and Raziel plan to file NDA with China's National Medical Products Administration",
    "GC Wellbeing expects increased demand for body-contouring treatments after weight loss"
  ],
  "editors_take": "The successful Phase 3 trial in China for RZL-012 paves the way for potential commercialization, bolstering GC Wellbeing's position in the growing medical aesthetics market, particularly in China and Korea.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}